U.S. Markets closed

ImmunoGen, Inc. (IMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.02+0.20 (+3.53%)
At close: 4:00PM EST

ImmunoGen, Inc.

830 Winter Street
Waltham, MA 02451-1477
United States
781 895 0600
http://www.immunogen.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees75

Key Executives

NameTitlePayExercisedYear Born
Mr. Mark J. EnyedyPres, CEO & Director1.2MN/A1964
Dr. Thomas RyllSr. VP of Technical Operations526.23kN/A1961
Dr. Anna BerkenblitSr. VP & Chief Medical Officer602.68kN/A1970
Ms. Susan Altschuller Ph.D.Sr. VP & CFON/AN/AN/A
Mr. David G. FosterVP of Fin. & Chief Accounting OfficerN/AN/AN/A
Ms. Courtney O'KonekSr. Director of Corp. Communications & Investor RelationsN/AN/AN/A
Ms. Audrey BerganVP & Chief HR OfficerN/AN/AN/A
Dr. Theresa G. WingroveSr. VP of Regulatory Affairs & QualityN/AN/A1958
Ms. Stacy A. CoenSr. VP & Chief Bus. OfficerN/AN/AN/A
Mr. Joseph J. KennySec.N/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Corporate Governance

ImmunoGen, Inc.’s ISS Governance QualityScore as of November 2, 2019 is 5. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 5; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.